Literature DB >> 27139507

Medical management of side effects related to CAR T cell therapy in hematologic malignancies.

Manjusha Namuduri1, Renier J Brentjens2,3,4.   

Abstract

Entities:  

Keywords:  CAR T cell; CD19; chimeric antigen receptor; cytokine release syndrome; immunotherapy

Mesh：

Substances：

Year:  2016        PMID： 27139507      PMCID： PMC5539903          DOI： 10.1080/17474086.2016.1183479

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


× No keyword cloud information.
  20 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

3.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

4.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Authors:  Xiuli Wang; Wen-Chung Chang; ChingLam W Wong; David Colcher; Mark Sherman; Julie R Ostberg; Stephen J Forman; Stanley R Riddell; Michael C Jensen
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

6.  Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children.

Authors:  Xiao-Jun Xu; Yong-Min Tang; Hua Song; Shi-Long Yang; Wei-Qun Xu; Ning Zhao; Shu-Wen Shi; He-Ping Shen; Jun-Qing Mao; Ling-Yan Zhang; Bin-Hua Pan
Journal:  J Pediatr       Date:  2012-01-09       Impact factor: 4.406

7.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

8.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

9.  Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome.

Authors:  Yongmin Tang; Xiaojun Xu; Hua Song; Shilong Yang; Shuwen Shi; Jian Wei; Binhua Pan; Fenying Zhao; Chan Liao; Chunfang Luo
Journal:  Br J Haematol       Date:  2008-07-31       Impact factor: 6.998

10.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113
View more
  15 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 2.  Pediatric hemophagocytic lymphohistiocytosis.

Authors:  Scott W Canna; Rebecca A Marsh
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

Review 3.  Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.

Authors:  Zohreh Sadat Badieyan; Sayed Shahabuddin Hoseini
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2018-02-09       Impact factor: 4.291

Review 4.  Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.

Authors:  Cristina Gutierrez; Colleen McEvoy; Laveena Munshi; R Scott Stephens; Michael E Detsky; Joseph L Nates; Stephen M Pastores
Journal:  Crit Care Med       Date:  2020-01       Impact factor: 7.598

Review 5.  Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.

Authors:  Ajeet Gajra; Abigail Zalenski; Aishwarya Sannareddy; Yolaine Jeune-Smith; Kandice Kapinos; Ankit Kansagra
Journal:  Pharmaceut Med       Date:  2022-06-07

6.  Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells.

Authors:  Margaret M Billingsley; Alex G Hamilton; David Mai; Savan K Patel; Kelsey L Swingle; Neil C Sheppard; Carl H June; Michael J Mitchell
Journal:  Nano Lett       Date:  2021-10-20       Impact factor: 12.262

Review 7.  Genetically enhanced T lymphocytes and the intensive care unit.

Authors:  Tiberiu Tat; Huming Li; Catalin-Sorin Constantinescu; Anca Onaciu; Sergiu Chira; Ciprian Osan; Sergiu Pasca; Bobe Petrushev; Vlad Moisoiu; Wilhelm-Thomas Micu; Cristian Berce; Sebastian Tranca; Delia Dima; Ioana Berindan-Neagoe; Jianliang Shen; Ciprian Tomuleasa; Liren Qian
Journal:  Oncotarget       Date:  2018-03-27

8.  Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Authors:  Frederick L Locke; Sattva S Neelapu; Nancy L Bartlett; Tanya Siddiqi; Julio C Chavez; Chitra M Hosing; Armin Ghobadi; Lihua E Budde; Adrian Bot; John M Rossi; Yizhou Jiang; Allen X Xue; Meg Elias; Jeff Aycock; Jeff Wiezorek; William Y Go
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

9.  Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

Authors:  Esther Drent; Renée Poels; Manon J Mulders; Niels W C J van de Donk; Maria Themeli; Henk M Lokhorst; Tuna Mutis
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

10.  The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.

Authors:  Michal P Kuczma; Zhi-Chun Ding; Tao Li; Tsadik Habtetsion; Tingting Chen; Zhonglin Hao; Locke Bryan; Nagendra Singh; James N Kochenderfer; Gang Zhou
Journal:  Oncotarget       Date:  2017-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.